A Multicentre, Randomized Controlled Study of Blood Clotting After transcatheter Closure of Atrial Septal Defect

A Multicentre, Control Study of Blood Clotting After transcatheter Closure of Atrial Septal Defect

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000346

Enrollment

Unknown

Registered

2009-03-17

Start date

2009-05-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Septal Defect

Interventions

Group A:Heparin injection 10 IU/kg/hr, Asprin oral administration 3mg/kg/d in 6 months.

Group B:Enoxaparin injection 1mg/kg 2 times in 24 hour, Asprin oral administration 3mg/kg/d in 6 months.

Group C:Enoxaparin injection 1mg/kg 2 times per day in 3 days. Asprin oral administration 3mg/kg/d in 6 months.

Eligibility

Sex/Gender

All

Age

6 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age>=3 years; diameter of defect >=5mm and increasing volume load of right heart; =5 mm, between artrial-ventricular valve >=7 mm; the diameter of defect>Occluder; no other cardiac anomalies need surgery intervention.

Exclusion criteria

Exclusion criteria: Hypertension, coronary artery disease, diabetes, atrial fibrillation and oral contraceptive medication, aspro, clopidogrel and warfarin in 2 weeks.

Design outcomes

Primary

Measure	Time frame
platelet activation;thrombozyme activation;Esophagus ultrasoun;	—

Secondary

Measure	Time frame
inflammatory factor;Anticoagulation fibronolysis;	—

Countries

China

Contacts

Public ContactLan Huang

huanglan260@yahoo.com.cn+86 023 68755614

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026